false
Catalog
Self-Assessment: Immune Mediated Peripheral Neurop ...
Immune Mediated Peripheral Neuropathies: Dr. Raja ...
Immune Mediated Peripheral Neuropathies: Dr. Raja Presentation
Back to course
Pdf Summary
The document outlines emerging therapies in autoimmune neuropathies as presented by Shruti M. Raja, MD, MHS, for the 2024 session. Dr. Raja has disclosed financial relationships as a consultant for companies like Regeneron, Signant Health, Ocaro Pharmaceuticals, and Ovid Therapeutics.<br /><br />Key therapeutic innovations include lymphocyte-directed treatments targeting B-cells, T-cells, and BAFF proteins; complement inhibition focusing on C1s, C5, and Factor B; traditional therapies with immunoglobulins, plasma exchange, and corticosteroids; and FcRn antagonism, with drugs like Efgartigimod (FDA approved), Rozanolizumab, Batoclimab, and Nipocalimab undergoing trials. B-cell depletion therapies employ monoclonal antibodies targeting CD19 and CD20, with Rituximab, Ocrelizumab, and Inebilizumab as noted examples. T-cell depletion and BAFF modulation were also discussed with advancements in bispecific antibodies to reduce autoimmunity without hampering immune response. Complement inhibition targets the pathways involved with supplements like Riliprubart (C1s inhibitor), Eculizumab, Ravulizumab, and Zilucoplan (C5 inhibitors).<br /><br />The document stresses the importance of continued clinical trials and research in optimizing dosing regimens, comparing routes of administration, and improving patient outcomes. It also notes the significance of evaluating antibody diversity while highlighting ongoing studies, such as TAK-771, to refine these therapies.<br /><br />Feedback from attendees of this session is requested via the AANEM app to enhance future presentations. Additionally, attendees are encouraged to use the app before October 19, 2025, to record session attendance for credit acquisition, with details on self-assessment and CNCT Checkpoint courses to follow post-event.
Keywords
autoimmune neuropathies
emerging therapies
B-cell depletion
T-cell depletion
complement inhibition
FcRn antagonism
clinical trials
monoclonal antibodies
lymphocyte-directed treatments
patient outcomes
2621 Superior Drive NW
Rochester, MN
P
507.288.0100
F
507.288.1225
aanem@aanem.org
Terms of Use
Privacy Statement
© 2024 American Association of Neuromuscular & Electrodiagnostic Medicine
×
Please select your language
1
English